Premature and full-term (FT) newborns recorded between January 2021 and January 2022 were included in this prospective study. Premature newborns were consecutively included for 8 months. Out of 210 premature newborns, 11 did not meet the inclusion criteria (congenital malformations, chromosomic anomalies, and digestive pathologies other than NEC), there were 13 cases of non-consent, and 29 samples were unavailable (insufficient amounts, technical problems). Full-term (FT) newborns were included consecutively for one month. Among the 280 newborns, 9 did not meet the inclusion criteria (congenital malformations, chromosomic anomalies, and digestive pathologies), there were 36 cases of non-consent, and 78 samples were unavailable. Newborns were considered premature if born before 37 gestational weeks (GW) and were classified into three groups: less than 28 GW (Group A), between 28 GW and 31 GW and 6 days (Group B), and between 32 GW and 36 GW and 6 days (Group C). Gestational weeks were calculated as amenorrhea weeks. Premature newborns under 22 GW and weighing less than 500 g were excluded. Full-term newborns (Group D) were recruited in two stages: a first cohort for tryptase assays and a second for calprotectin (tryptase and calprotectin populations). Newborns were considered hypotrophic when their BW was below the 10th percentile.
Free full text: Click here